Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine And Low Dose TBI With Disease-Risk Based Immunosuppression

Trial Profile

Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine And Low Dose TBI With Disease-Risk Based Immunosuppression

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2016

At a glance

  • Drugs Fludarabine (Primary) ; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil
  • Indications Amyloidosis; Chronic lymphocytic leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2012 Planned end date changed from 1 Dec 2003 to 1 Feb 2005 as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Planned end date (1 Dec 2003) added as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Actual patient number (159) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top